Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in the Treatment of HIV-Infected Patients: Experience with the First 100 Patients from Qatar
Table 1
Baseline characteristics of HIV-infected patients.
Characteristics
Number
Sex
Male
80
Female
20
Age
Mean (years)
40
Range
14–80
Nationality
Qatar
64
GCC
3
Pakistan
6
Philippine
5
Palestine
3
Others
19
Year of diagnosis
<2000
14
>2000
86
Indication for switch to EVG/COBI/FTC/TAF
New case
29
Side effects of previous regimen
13
Treatment failure
2
Drug interaction
1
Simplicity
14
Safety
40
Non‐compliance with previous regimen
1
Previous regimen
Atripla
32
Darunavir/ritonavir plus Truvada
2
Atazanavir/ritonavir plus Truvada
3
Stribild
18
Kaletra plus Truvada
2
Raltegravir plus Truvada
10
Others
4
Year of starting EVG/COBI/FTC/TAF
2016
49
2017
40
2018
11
Viral load at time of starting EVG/COBI/FTC/TAF
Undetectable
55
Detectable
44
Range (51–836648 copies/ml)
Not recorded
1
CD + 4 cell count at time of starting EVG/COBI/FTC/TAF
